ALSO NOTED: Actavis shareholder pushes bolder strategy; Texas lawmakers back $3B cancer initiative; and much more...

> Live from BIO: A total of 22,366 people turned out for BIO 2007, a 15 percent increase over last year's conference. A third of the attendees came from outside the U.S. Release

> The largest shareholder in Finland's Actavis Group is bidding to buy up all remaining Class A shares in a bid to push the company to adopt a bolder corporate strategy. Report

> Support for a $3 billion effort to find a cure for cancer in Texas has gained support in the state House. Report

> Eli Lilly has followed IBM in laying out a formal policy excluding genetic data from decisions about employment and insurance coverage. Report

> Geron is advancing plans to file an IND with the FDA for an embryonic stem cell therapy for spinal injuries. Report

> Cell Genesys has outlined three trials underway for its leukemia drug GVAX. Report

> Canada's Asmacure Ltée announced a Series A round of financing of $9 million involving Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec City, and Domain Associates from Princeton, New Jersey. Release

> Drug Royalty Corporation has acquired the future right to receive royalties on the sale of Enbrel from the Massachusetts General Hospital. Release

> Evotec announced today that Panacos Pharmaceuticals has extended its ongoing discovery collaboration with Evotec into its fourth year. Release 

And Finally… Swedish smokeless tobacco--called snus--is far less likely to cause cancer than traditional tobacco, according to physicians writing in The Lancet. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.